Abstracts tagged "Autoantibody(ies)"

Abstract Number: 0631 • ACR Convergence 2025
Antibodies to Type I and Type III Interferons at Diagnosis Predispose to Serious Infections on Follow Up in an Inception cohort of SLE (INSPIRE) from India.
Rudrarpan Chatterjee¹, Komal Singh², Ranjan Gupta³, Sudhir Sinha⁴ and Amita Aggarwal⁵, ¹Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow., Lucknow, Uttar Pradesh, India, ²Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Lucknow, Uttar Pradesh, India, ³All India Institute of Medical Sciences, New Delhi, Delhi, India, ⁴Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Lucknow, India, ⁵Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India
Background/Purpose: Patients with systemic lupus erythematosus (SLE) are predisposed to infections due to immune dysregulation. Autoantibodies to cytokines can cause serious infections, including severe COVID-19,…
Abstract Number: 1174 • ACR Convergence 2025
High Prevalence of Autoimmunity in Rosai Dorfman Disease: A Multinational Study
Mitali Sen¹, Gordon Ruan², Samuel Reynolds³, Haadi Ali³, Xi Yang³, Diana Morlote¹, Aishwarya Ravindran¹, Lauren Shea¹, Matthew Koster⁴, Jithma Abeykoon², Hind Salama⁵, Xin-Xin Cao⁶, Asra Ahmed³, Ronald Go² and Gaurav Goyal¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Mayo Clinic, Rochester, ³University of Michigan, Michigan, ⁴Mayo Clinic, Rochester, MN, ⁵National Guard Health Affairs, Riyadh, Saudi Arabia, ⁶Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China (People's Republic)
Background/Purpose: Rosai-Dorfman Disease (RDD), formerly known as sinus histiocytosis with massive lymphadenopathy, was initially thought to be inflammatory or autoimmune in nature. The discovery of…
Abstract Number: 1591 • ACR Convergence 2025
Novel autoantibodies in patients with systemic sclerosis and gastrointestinal dysfunction provide insight into disease pathogenesis
Zsuzsanna McMahan¹, Claudia Pedroza², Katie Lee³, Bingrui Chen³, Ami Shah⁴, Jody Hooper⁵, Srinivas Puttapaka⁶, Livia Casciola-Rosen⁷ and Subhash Kulkarni⁸, ¹UT Health Houston, Houston, TX, ²UTHealth Houston Institute for Clinical Research & Learning Health Care, Texas, TX, ³UTHealth Houston, Houston, TX, ⁴Johns Hopkins Rheumatology, Baltimore, MD, ⁵Stanford University, Stanford, CA, ⁶BIDMC/Harvard, Boston, MA, ⁷Johns Hopkins University, Baltimore, MD, ⁸BIDMC, Boston, MA
Background/Purpose: Gastrointestinal (GI) dysfunction is common and often debilitating in systemic sclerosis (SSc). Though it affects most patients, mechanisms are poorly understood and biomarkers for…
Abstract Number: 2062 • ACR Convergence 2025
Immune Cell Signatures Associated with Disease Activity in Dermatomyositis Across Autoantibody Subtypes
Jeffrey Sagun¹, Melissa Leeolou¹, Nicholas Geraci², Andrew Bender³, Fatima Strand², David Fiorentino¹ and Kavita Sarin¹, ¹Department of Dermatology, Stanford University Medical Center, Stanford, CA, ²EMD Serono, Billerica, MA, ³AbbVie, Worcester, MA
Background/Purpose: Dermatomyositis (DM) is a heterogeneous multisystem autoimmune disease characterized by inflammation of the skin, muscle, and lung. Identifying the immune cells that drive disease…
Abstract Number: 2434 • ACR Convergence 2025
Specificity of Cell-bound T Cell Biomarkers (TC4d, TIgG, TIgM) in Differentiating SLE from ANA-Associated Rheumatic Diseases
Vasileios Kyttaris¹, Sepehr Taghavi², Clayton Nagle³, Christine Schleif³, Brittany Partain⁴ and Tyler O'Malley⁵, ¹Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, ²Exagen Inc, Escondido, CA, ³Exagen, Carlsbad, CA, ⁴Exagen, Boston, MA, ⁵Exagen, Vista, CA
Background/Purpose: We previously validated T Cell-bound C4d (TC4d), T Cell-bound IgG (TIgG), and T Cell-bound IgM (TIgM) biomarkers, demonstrating high sensitivity and specificity for differentiating…
Abstract Number: 0121 • ACR Convergence 2025
The Prevalence and Clinical Significance of IgA Anticardiolipin and Anti-β2-Glycoprotein-I Antibody Isotypes in Antiphospholipid Antibody Positive Patients: Descriptive Results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking Registry
Emre Sahin¹, Yu (Ray) Zuo², Danieli Andrade³, Maria Tektonidou⁴, Vittorio Pengo⁵, Massimo Radin⁶, Chary López pedrera⁷, Diana Paredes-Ruiz⁸, H Michael Belmont⁹, Paul Fortin¹⁰, Denis WAHL¹¹, Ware Branch¹², Maria Gerosa¹³, Guilherme Ramires de Jesus¹⁴, Tatsuya Atsumi¹⁵, Maria Efthymiou¹⁶, Angela Tincani¹⁷, Esther Rodriguez-Almaraz¹⁸, Michelle Petri¹⁹, Ricard Cervera²⁰, Rohan Willis²¹, Katrien Devreese²², Maria Laura Bertolaccini²³, Hannah Cohen²⁴, Jason S. Knight² and Doruk Erkan¹, ¹Hospital for Special Surgery, New York, NY, ²University of Michigan, Ann Arbor, MI, ³University of Sao Paulo, São Paulo, São Paulo, Brazil, ⁴National and Kapodistrian University of Athens, Athens, Greece, ⁵Padova University Hospital, Padova, Italy, ⁶University of Turin, Turin, Turin, Italy, ⁷Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain, ⁸Biobizkaia Health Research Institute, Barakaldo, Spain, ⁹NYU School of Medicine, New York, NY, ¹⁰Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, ¹¹University of Lorraine, Nancy, France, ¹²University of Utah Health Sciences Center, Salt Lake City, UT, ¹³University of Milan, Milano, Italy, ¹⁴Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Rio de Janeiro, Brazil, ¹⁵Hokkaido University, Sapporo, Japan, ¹⁶University College London, London, United Kingdom, ¹⁷ASST Spedali Civili-University of Brescia, Gussago, Brescia, Italy, ¹⁸Hospital Universitario ¹² de Octubre, Madrid, Spain, ¹⁹Johns Hopkins University School of Medicine, Timonium, MD, ²⁰Hospital Clinic Barcelona, Barcelona, Spain, ²¹University of Texas Medical Branch, Galveston, TX, ²²Ghent University, Gent, Belgium, ²³King's College London, London, United Kingdom, ²⁴University College London Hospitals NHS Foundation Trust, London, United Kingdom
Background/Purpose: The 2023 ACR/EULAR Antiphospholipid Syndrome (APS) Classification Criteria (CC) focus on IgG and IgM anticardiolipin (aCL) and anti-β2-glycoprotein-I antibodies (aβ2GPI). IgA isotypes were excluded…
Abstract Number: 0506 • ACR Convergence 2025
Discovery-based Identification of Non-canonical Autoantibody Specificities in Ro Seronegative Sjögren’s Disease Using High-content Human Proteome Arrays
Songyuan Yao¹, Christina Lawrence¹, Hope Christakos², Charmaine Lopez-Davis¹, Bhuwan Khatri¹, Tommi C. Taylor¹, Astrid Rasmussen¹, Kiely Grundahl², R Hal Scofield¹, Blake M. Warner³, Judith James¹, Joel Guthridge¹, Christopher J. Lessard¹ and A. Darise Farris¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma City, ³National Institutes of Health, Bethesda, MD
Background/Purpose: Clinical tests for Sjögren’s disease (SjD) often overlook Ro-seronegative (RoNeg) cases, leading to delayed or missed diagnoses. Identifying additional serum autoantibodies could improve diagnostic…
Abstract Number: 0646 • ACR Convergence 2025
A-319, a CD3×CD19 T Cell Engager, for the Treatment of Refractory Systemic Lupus Erythematosus: Preliminary Evidence of Autoimmune Reset
Chunli Mei¹, Xin Guan¹, Rong Du¹, Bin Wu², You Song¹, Xiaoqi Chen³, Mengjiao Li¹, Xiaojing Liu¹, Xi Cheng¹, Weiwei Wang¹, Cheng Wang¹, Huiling Mei¹, Xiaoru Duan¹, Lijuan Jiang¹, Wenlin Qiu¹, Likai Yu¹, Yuhong Liu¹, Di Wu¹, Guiqi Quan¹, Blal Chakhabi¹, Xing Zhao⁴, Xuanfan Zhong⁴, Shengjie Xue⁴, Wuzhong Shen⁴, Ying Tan⁴, Guojian Yu⁴, Guiyun Tu⁴, Hanyang Chen⁴, Amy Sun⁴, Jing Liang⁴, Sharon Song⁴, Jason Xu⁴, Xiaoqiang Yan⁴, Anbing Huang¹ and Qiubai Li⁵, ¹Union Hospital,Tongji Medical College, Huazhong University of Science and Technology, WUHAN, China (People's Republic), ²First People’s Hospital of Jingzhou, Jingzhou, China (People's Republic), ³Zhongnan Hospital, Wuhan University, Wuhan, China (People's Republic), ⁴ITabMed Co., Ltd., Shanghai, China (People's Republic), ⁵Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China (People's Republic)

Background/Purpose: Immune reset of autoimmune disease has been proposed to be a potential benefit of T cell engagers (TCEs) and CD19 CAR T therapy. A-319,…
Abstract Number: 1187 • ACR Convergence 2025
Myositis-Specific Antibody Profiles and Factors Associated With Rapidly Progressive Interstitial Lung Disease and Mortality in Antisynthetase Syndrome: A Systematic Review and Meta-Analysis
Tulaton Sodsri¹, Nattanicha Chaisrimaneepan², Ben Thiravetyan³, Rabhas Boonyawairote⁴, Nopavit Mohpichai⁵, Nutchapon Xanthavanij⁶, Natnicha Jakramonpreeya⁷, Pintip Ngamjanyaporn⁸ and Tananchai Petnak⁸, ¹Department of Medicine, Texas Tech University Health Sciences Center, Bangkok, Thailand, ²Department of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, ³Department of Medicine, Texas Tech University Health Sciences Center, Lubbock, ⁴University of Illinois at Chicago, Chicago, ⁵Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand, ⁶Mount Auburn Hospital, Harvard Medical School, Cambridge, ⁷Chakri Naruebodindra Medical Institute, Bangkok, Thailand, ⁸Ramathibodi Hospital, Bangkok, Thailand
Background/Purpose: The associations between various myositis-specific antibodies (MSAs), rapidly progressive interstitial lung disease (RP-ILD), and mortality in antisynthetase syndrome (ASS) have been previously reported in…
Abstract Number: 1678 • ACR Convergence 2025
Abatacept in individuals at risk of developing rheumatoid arthritis: results from the Arthritis Prevention in the Pre-clinical Phase of RA with Abatacept Long Term Outcomes (ALTO) Study
Andrew Cope¹, Joana Vasconcelos¹, Marianna Jasenecova², Andrew Filer³, Karim Raza⁴, Sumera Qureshi¹, Maria Antonietta D'Agostino⁵, Iain McInnes⁶, Stefan Siebert⁶, John Isaacs⁷, Arthur Pratt⁸, Benjamin A. Fisher⁹, Christopher Buckley¹⁰, Paul Emery¹¹, Kulveer Mankia¹¹, Pauline Ho¹², MAYA BUCH¹³, Coziana Ciurtin¹⁴, Dirkjan van Schaardenburg¹⁵, Tom Huizinga¹⁶, René Toes¹⁶, Caroline Murphy¹ and A. Toby Prevost¹, ¹King's College London, London, United Kingdom, ²King's College London, London, ³The University of Birmingham, Birmingham, United Kingdom, ⁴University of Birmingham, Birmingham, United Kingdom, ⁵Division of Rheumatology and Clinical Immunology - Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ⁶University of Glasgow, Glasgow, United Kingdom, ⁷Newcastle University, Newcastle upon Tyne, United Kingdom, ⁸University of Newcastle, Newcastle, United Kingdom, ⁹King’s College London, London, UK; Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK, Birmingham, United Kingdom, ¹⁰University of Oxford, Oxford, United Kingdom, ¹¹University of Leeds, Leeds, England, United Kingdom, ¹²The Kellgren Centre for Rheumatology, Manchester Royal Infirmary, Manchester, United Kingdom, ¹³UNIVERSITY OF MANCHESTER, MANCHESTER, United Kingdom, ¹⁴University College London, London, ¹⁵Amsterdam UMC, Amsterdam, Netherlands, ¹⁶Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Clinical trials aimed at delaying or preventing rheumatoid arthritis (RA) in individuals at risk have been published with variable results. In the APIPPRA study,…
Abstract Number: 2075 • ACR Convergence 2025
Ferritin trends differentiate anti-MDA5 Dermatomyositis from anti-Jo1 Antisynthetase Syndrome
Silvia Grazzini¹, Edoardo Conticini¹, Marco Fornaro², Chiara Rizzo³, Lidia La Barbera³, Maria Rosa Pellico⁴, Stefano Stano⁵, Florenzo Iannone⁶, Giuliana Guggino³, Nicoletta Del Papa⁴, Luca Cantarini⁷ and Bruno Frediani⁷, ¹Rheumatology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Italy, Siena, Italy, ²Unit of Rheumatology, Department of Precision and Regenerative Medicine, Area Jonica (DiMePRe-J), University of Bari, Italy., Bari, Italy, ³Rheumatology Unit, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE) University of Palermo, Palermo, Italy, ⁴ASST Pini-CTO, Clinical Rheumatology Unit, Milano, Italy, ⁵⁶. Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari, Bari, Italy, ⁶Rheumatology DiMePReJ, University of Bari, School of Medicine, Bari, Italy, Bari, Italy, ⁷Rheumatology Unit, Department of Medicine, Surgery and Neurosciences, University Hospital of Siena, Siena, Italy, Siena, Italy
Background/Purpose: Serum ferritin (FERR) is a recognized marker of immune activation and a key laboratory feature of anti-MDA5 Dermatomyositis (DM). It has been increasingly studied…
Abstract Number: 2474 • ACR Convergence 2025
Unveiling the clinical spectrum of ACA-positive SSc-ILD: not as benign as expected
Carlos Valera Ribera¹, JUAN JOSE ALEGRE SANCHO², Ivan Castellvi³, Marta Ibañez⁴ and Javier Narváez⁵, ¹Hospital Universitario Doctor Peset, València, Spain, ²Department of rheumatology. Hospital Universitario Doctor Peset, Valencia, Spain, ³Hospital Universitari de la Santa Creu i Sant Pau, Sant Just Desvern, Spain, ⁴Hospital Universitario de la Santa Creu i Sant Pau, Barcelona, Catalonia, Spain, ⁵Hospital Universitario de Bellvitge, Barcelona, Spain
Background/Purpose: Anticentromere antibody (ACA)-positive interstitial lung disease (ILD) in systemic sclerosis (SSc) is traditionally considered less aggressive than anti-topoisomerase I (ATA)-positive ILD. However, its clinical…
Abstract Number: 0129 • ACR Convergence 2025
Analysis of Antiphosphatidylserine/prothrombin Antibodies as a Predictor of Lupus Anticoagulant in the Pediatric Population
Jonathan Marilao¹, Sean Yates² and Elizabeth Sloan³, ¹University of Texas Southwestern, Dallas, TX, ²University of Texas Southwestern, Dallas, ³UT Southwestern, Children's Medical Center, and Scottish Rite for Children, Dallas, TX
Background/Purpose: Antiphospholipid Syndrome (APS) is a systemic thromboinflammatory autoimmune disease characterized by thrombotic or obstetric events occurring in individuals with persistently positive antiphospholipid antibodies (aPL).…
Abstract Number: 0509 • ACR Convergence 2025
Functional Anti-M3R Autoantibodies in Sjögren’s Disease: From Gland to Circulation
Martha Tsaliki¹, Joshua Cavett², Biji T Kurien³, valerie Lewis³, John Ice⁴, Devavrat Dave⁵, Sina Khosravani⁵, Menerva Racy⁵, Rebecca Wood⁶, Seunghee Cha⁷, A. Darise Farris³, Kristi A. Koelsch⁵ and R. Scofield³, ¹The University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²Oklahoma Medicar Research Foundtion, Oklahoma City, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴OKC Veterans Affairs Medical Center, Oklahoma City, OK, ⁵Oklahoma Medical Research Foundation, oklahoma City, ⁶University of Oklahoma Health Sciences Center, Edmond, OK, ⁷University of Florida, Gainesville
Background/Purpose: Sjögren’s disease (SjD) is a systemic autoimmune disease characterized by immune-mediated damage to salivary and lacrimal glands. While autoantibodies against muscarinic type 3 receptor…
Abstract Number: 0654 • ACR Convergence 2025
Obinutuzumab Shows Promise in Lupus Nephritis Regardless of Baseline Serological Markers: An Exploratory Post Hoc Analysis of a Phase II Trial
Ed Vital¹, Benni Vargas², Julie Rae², Tracey Wang³, Jason Hackney², Cary Looney⁴, William Pendergraft², Liz Lightstone⁵, Brad Rovin⁶, Richard Furie⁷ and Harini Raghu², ¹University of Leeds, Leeds, England, United Kingdom, ²Genentech, Inc., South San Francisco, CA, ³Hoffmann-La Roche Ltd, Missssauga, ON, Canada, ⁴F. Hoffmann-La Roche Ltd, Basel, Switzerland, ⁵Department of Immunology and Inflammation, Faculty of Medicine, Imperial College London, London, England, United Kingdom, ⁶The Ohio State University, Columbus, OH, ⁷Division of Rheumatology, Northwell Health, Great Neck, NY
Background/Purpose: Lupus nephritis (LN) is characterized by kidney inflammation. B cells play a central role in LN pathogenesis and type I interferon (IFN-I) pathway activation…

« Previous Page
1
…
3
4
5
6
7
…
37
Next Page »

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].